Dimensional Fund Advisors LP lifted its stake in Medidata Solutions Inc (NASDAQ:MDSO) by 55.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 224,308 shares of the company’s stock after buying an additional 80,395 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.37% of Medidata Solutions worth $15,122,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Virginia Retirement Systems ET AL acquired a new position in shares of Medidata Solutions in the 4th quarter worth approximately $452,000. BlackRock Inc. raised its stake in Medidata Solutions by 2.9% during the 4th quarter. BlackRock Inc. now owns 6,995,601 shares of the company’s stock valued at $471,644,000 after acquiring an additional 195,763 shares in the last quarter. American International Group Inc. raised its stake in Medidata Solutions by 1.9% during the 4th quarter. American International Group Inc. now owns 161,630 shares of the company’s stock valued at $10,897,000 after acquiring an additional 3,091 shares in the last quarter. Prudential PLC raised its stake in Medidata Solutions by 104.5% during the 4th quarter. Prudential PLC now owns 129,435 shares of the company’s stock valued at $8,727,000 after acquiring an additional 66,155 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Medidata Solutions by 62.8% during the 4th quarter. Rhumbline Advisers now owns 183,326 shares of the company’s stock valued at $12,360,000 after acquiring an additional 70,690 shares in the last quarter.
In other news, Director Robert Taylor sold 3,294 shares of Medidata Solutions stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the transaction, the director now owns 41,757 shares in the company, valued at $3,794,876.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.70% of the company’s stock.
Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. The company had revenue of $173.50 million for the quarter, compared to analyst estimates of $172.12 million. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. Medidata Solutions’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.40 earnings per share. As a group, research analysts anticipate that Medidata Solutions Inc will post 0.79 EPS for the current year.
Several analysts have weighed in on MDSO shares. SunTrust Banks lifted their target price on Medidata Solutions from $85.00 to $92.25 and gave the company a “hold” rating in a research note on Thursday, June 13th. BidaskClub raised Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 20th. Piper Jaffray Companies downgraded Medidata Solutions from an “overweight” rating to a “neutral” rating in a research note on Wednesday, June 12th. William Blair downgraded Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 12th. Finally, Dougherty & Co downgraded Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $84.24.
Medidata Solutions Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.